{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:55:18Z","timestamp":1783000518328,"version":"3.54.5"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective:<\/jats:title><jats:p>The aim of this study was to investigate the effects of elobixibat on constipation and lipid metabolism; and determine the factors associated with the effect of elobixibat on constipation in patients with moderate to end-stage chronic kidney disease (CKD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3, 6; stage G4, 9; stage G5, 9; stage G5D, 18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Elobixibat increased stool frequency from 0.5 \u00b1 0.4 per day to 1.1 \u00b1 0.6 per day (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) regardless of whether patients were undergoing dialysis, on concomitant laxatives, or were administered elobixibat before or after breakfast. Elobixibat reduced low-density lipoprotein cholesterol concentration (from 90.9 \u00b1 37.2 mg\/dL to 77.5 \u00b1 34.8 mg\/dL, <jats:italic>p<\/jats:italic> &amp;lt; 0.05) and increased high-density lipoprotein cholesterol concentration (from 44.9 \u00b1 14.3 mg\/dL to 57.0 \u00b1 25.8 mg\/dL, <jats:italic>p<\/jats:italic> &amp;lt; 0.05), but did not change triglyceride concentration. Adverse effects were observed in two patients (nausea and diarrhea). Only phosphate concentration was correlated with the change in stool frequency after initiation of elobixibat (standard coefficient = 0.321, <jats:italic>p<\/jats:italic> = 0.043).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Elobixibat improved constipation and lipid metabolism in patients with moderate to end-stage CKD, without serious adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.780127","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T04:44:06Z","timestamp":1642394646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Momoko","family":"Matsuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeka","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mutsuyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Aomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ookawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1681\/ASN.2016060656","article-title":"Constipation and incident CKD","volume":"28","author":"Sumida","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2018.12.021","article-title":"Constipation and risk of death and cardiovascular events","volume":"281","author":"Sumida","year":"2019","journal-title":"Atherosclerosis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1365-2036.2010.04273.x","article-title":"Systematic review: impact of constipation on quality of life in adults and children","volume":"31","author":"Belsey","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12876-021-01684-x","article-title":"Higher frailty burden in older adults with chronic constipation","volume":"21","author":"Lim","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12876-020-01425-6","article-title":"Factors correlated with drug use for constipation: perspectives from the 2016 open Japanese National Database","volume":"20","author":"Mihara","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/nu13020421","article-title":"Magnesium oxide in constipation","volume":"13","author":"Mori","year":"2021","journal-title":"Nutrients."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/BF02234645","article-title":"Adverse effects of laxatives","volume":"44","author":"Xing","year":"2001","journal-title":"Dis Colon Rectum."},{"key":"B8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/17474124.2018.1522248","article-title":"Elobixibat for the treatment of constipation","volume":"12","author":"Chedid","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/bcp.13698","article-title":"Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial","volume":"84","author":"Kumagai","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e43749","DOI":"10.1371\/journal.pone.0043749","article-title":"Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12876-020-1179-6","article-title":"Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study","volume":"20","author":"Kamei","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.kint.2020.01.032","article-title":"Lithocholic acid increases intestinal phosphate and calcium absorption in a vitamin D receptor dependent but transcellular pathway independent manner","volume":"97","author":"Hashimoto","year":"2020","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1756283X14528269","article-title":"Elobixibat and its potential role in chronic idiopathic constipation","volume":"7","author":"Acosta","year":"2014","journal-title":"Therap Adv Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9656040","DOI":"10.1155\/2020\/9656040","article-title":"The efficacy and safety of elobixibat for the elderly with chronic constipation: a multicenter retrospective cohort study","volume":"2020","author":"Tomie","year":"2020","journal-title":"Gastroenterol Res Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41100-020-00267-y","article-title":"Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study","volume":"6","author":"Shono","year":"2020","journal-title":"Renal Replacement Therapy."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.780127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T04:44:09Z","timestamp":1642394649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.780127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":18,"alternative-id":["10.3389\/fmed.2021.780127"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.780127","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"780127"}}